CCM
SNDX icon

CAAS Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

CAAS Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-344,168
Closed -$8.76M – 890
2022
Q4 		$8.76M Buy
+344,168
New +$8.03M 0.53% 47
2022
Q1 		– Sell
-26,376
Closed -$577K – 905
2021
Q4 		$577K Buy
+26,376
New +$487K 0.01% 522

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

CAAS Capital Management's SNDX Position: Q1 2023 in Review

CAAS Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2023, closing a stake of 344,168 shares — an estimated $8.76M sold.

CAAS Capital Management first reported a position in SNDX in Q4 2021 and held it in 2 quarters. The position peaked at $8.76M in Q4 2022. 163 funds tracked by Wall St. Rank hold SNDX as of Q1 2023.

  • CAAS Capital Management reported no remaining Syndax Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 344,168 Syndax Pharmaceuticals shares in Q1 2023, an estimated $8.76M.
  • CAAS Capital Management first reported a position in Syndax Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • CAAS Capital Management's Syndax Pharmaceuticals position peaked at $8.76M in Q4 2022.
  • 163 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.